Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.
Stocks · News reference
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA
Dollar General, Bristol-Myers Squibb, and Equinor ASA have received broker rating upgrades despite macroeconomic headwinds. All three stocks show positive earnings growth expectations and improved analyst sentiment, with Equinor showing the strongest projected earnings growth at 120.7% year-over-year.
Bristol-Myers Squibb shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $73 to $59.
Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177
Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.
Halozyme Says Dutch Court Upholds Its Patent, Bars Merck From Making And Selling Keytruda SC In Multiple European Markets
Tempus Announces Expanded Collaboration With Merck And Moderna For Potential Commercialization Of Cancer Vaccine Intismeran Autogene; Terms Not Disclosed